Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Temozolomide in Metastatic Melanoma
NCT00715793Phase 2Completed
- Start
- Jun 2008
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine in melanoma. Primary endpoints: Dose Limiting Toxicity up to 26 months, Overall Response Rate up to 30 months and 1 more. Started Jun 2008; status: completed.
02
Drugs
decitabine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00715793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00715793.